Vanda Pharmaceuticals (VNDA) Competitors

Vanda Pharmaceuticals logo
$3.81 -0.18 (-4.51%)
Closing price 04:00 PM Eastern
Extended Trading
$3.81 0.00 (-0.08%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VNDA vs. IVA, ANRO, TBPH, ARDX, and COLL

Should you buy Vanda Pharmaceuticals stock or one of its competitors? Vanda Pharmaceuticals's main competitors and comparable companies include Inventiva (IVA), Alto Neuroscience (ANRO), Theravance Biopharma (TBPH), Ardelyx (ARDX), and Collegium Pharmaceutical (COLL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vanda Pharmaceuticals compare to Inventiva?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Inventiva has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -119.87%. Inventiva's return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vanda Pharmaceuticals-119.87% -62.70% -37.53%
Inventiva N/A N/A N/A

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Inventiva. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 2 mentions for Inventiva. Vanda Pharmaceuticals' average media sentiment score of 0.89 beat Inventiva's score of 0.42 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Inventiva
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Vanda Pharmaceuticals has higher revenue and earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$216.10M1.12-$220.47M-$4.62N/A
Inventiva$49K17,960.50-$400.67MN/AN/A

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vanda Pharmaceuticals currently has a consensus target price of $13.50, indicating a potential upside of 238.35%. Inventiva has a consensus target price of $14.67, indicating a potential upside of 298.55%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Vanda Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Inventiva
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

Vanda Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Summary

Inventiva beats Vanda Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Alto Neuroscience?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, Alto Neuroscience had 21 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 24 mentions for Alto Neuroscience and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.89 beat Alto Neuroscience's score of 0.74 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alto Neuroscience
3 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alto Neuroscience has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -119.87%. Alto Neuroscience's return on equity of -41.82% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vanda Pharmaceuticals-119.87% -62.70% -37.53%
Alto Neuroscience N/A -41.82%-36.56%

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alto Neuroscience has lower revenue, but higher earnings than Vanda Pharmaceuticals. Alto Neuroscience is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$216.10M1.12-$220.47M-$4.62N/A
Alto NeuroscienceN/AN/A-$63.24M-$2.44N/A

Vanda Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Vanda Pharmaceuticals presently has a consensus price target of $13.50, indicating a potential upside of 238.35%. Alto Neuroscience has a consensus price target of $37.88, indicating a potential upside of 27.42%. Given Vanda Pharmaceuticals' higher probable upside, equities research analysts clearly believe Vanda Pharmaceuticals is more favorable than Alto Neuroscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Alto Neuroscience
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

Summary

Alto Neuroscience beats Vanda Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Theravance Biopharma?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vanda Pharmaceuticals currently has a consensus target price of $13.50, suggesting a potential upside of 238.35%. Theravance Biopharma has a consensus target price of $19.00, suggesting a potential upside of 11.57%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Vanda Pharmaceuticals is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Theravance Biopharma
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Theravance Biopharma has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$216.10M1.12-$220.47M-$4.62N/A
Theravance Biopharma$104.31M8.48$105.89M$1.0116.86

Vanda Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 2 mentions for Theravance Biopharma. Vanda Pharmaceuticals' average media sentiment score of 0.89 beat Theravance Biopharma's score of 0.54 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Theravance Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Theravance Biopharma has a net margin of 51.58% compared to Vanda Pharmaceuticals' net margin of -119.87%. Theravance Biopharma's return on equity of -0.77% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vanda Pharmaceuticals-119.87% -62.70% -37.53%
Theravance Biopharma 51.58%-0.77%-0.46%

Summary

Vanda Pharmaceuticals and Theravance Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Ardelyx?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Ardelyx had 23 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 26 mentions for Ardelyx and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.89 beat Ardelyx's score of 0.09 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ardelyx
2 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vanda Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Ardelyx has a net margin of -11.85% compared to Vanda Pharmaceuticals' net margin of -119.87%. Ardelyx's return on equity of -35.30% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vanda Pharmaceuticals-119.87% -62.70% -37.53%
Ardelyx -11.85%-35.30%-10.23%

Ardelyx has higher revenue and earnings than Vanda Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$216.10M1.12-$220.47M-$4.62N/A
Ardelyx$407.32M1.91-$61.60M-$0.22N/A

Vanda Pharmaceuticals presently has a consensus price target of $13.50, suggesting a potential upside of 238.35%. Ardelyx has a consensus price target of $13.60, suggesting a potential upside of 340.13%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Vanda Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Ardelyx
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92

Summary

Ardelyx beats Vanda Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Collegium Pharmaceutical has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$780.57M1.01$62.87M$1.0025.32
Vanda Pharmaceuticals$216.10M1.12-$220.47M-$4.62N/A

Collegium Pharmaceutical currently has a consensus target price of $44.88, suggesting a potential upside of 77.23%. Vanda Pharmaceuticals has a consensus target price of $13.50, suggesting a potential upside of 238.35%. Given Vanda Pharmaceuticals' higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

In the previous week, Collegium Pharmaceutical had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.89 beat Collegium Pharmaceutical's score of 0.26 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Collegium Pharmaceutical
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Collegium Pharmaceutical has a net margin of 4.68% compared to Vanda Pharmaceuticals' net margin of -119.87%. Collegium Pharmaceutical's return on equity of 85.14% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical4.68% 85.14% 13.80%
Vanda Pharmaceuticals -119.87%-62.70%-37.53%

Summary

Collegium Pharmaceutical beats Vanda Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VNDA vs. The Competition

MetricVanda PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$238.85M$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E RatioN/A26.0432.9127.37
Price / Sales1.077.318.595.73
Price / CashN/A15.7421.9322.50
Price / Book1.155.144.403.70
Net Income-$220.47M$2.88B$3.52B$392.17M
7 Day Performance-6.85%-3.87%-5.34%-4.53%
1 Month Performance-5.46%-3.96%-3.61%-5.86%
1 Year Performance-12.41%-7.13%0.01%-7.78%

Vanda Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VNDA
Vanda Pharmaceuticals
4.0767 of 5 stars
$3.81
-4.5%
$13.50
+254.3%
-8.3%$238.85M$216.10MN/A533
IVA
Inventiva
2.6693 of 5 stars
$3.84
+1.1%
$14.67
+281.9%
-8.0%$921.01M$5.07MN/A77
ANRO
Alto Neuroscience
2.0901 of 5 stars
$27.57
+9.6%
$37.88
+37.4%
+147.5%$914.34MN/AN/A68
TBPH
Theravance Biopharma
1.5483 of 5 stars
$17.03
flat
$19.00
+11.6%
N/A$884.18M$104.31M16.86110
ARDX
Ardelyx
3.5533 of 5 stars
$2.93
+1.7%
$13.90
+374.4%
-47.3%$827.02M$407.32MN/A489

Related Companies and Tools


This page (NASDAQ:VNDA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners